4 pharmaceutical companies reported good annual results, and 1 traditional Chinese medicine company's net profit increased by over 900%

Recently, the disclosure of 2021 annual reports of listed pharmaceutical companies has continued
.
It was reported on March 28 that four other pharmaceutical companies, Dong’e Ejiao, China Resources Sanjiu, Tiger Pharmaceuticals, and Livzon Pharmaceutical, released their annual results, and they all reported good news.
Among them, the year-on-year growth of Dong’e Ejiao in 2021 was more than 900%.
%
.
Dong’e Ejiao: Net profit increased by more than 900% year-on-year.
As of December 31, 2021, Dong’e Ejiao obtained a total operating income of 3.
849 billion yuan, an increase of 12.
89% year-on-year; the net profit attributable to shareholders of listed companies was 440 million yuan, a year-on-year increase of 440 million yuan.
An increase of 917.
43%; basic earnings per share are 0.
68 yuan, and a cash dividend of 6.
5 yuan (tax included) is proposed for every 10 shares
.
According to the announcement, the substantial increase in performance is mainly due to the rebound in sales of main products in 2021, of which the pharmaceutical business has increased by 510 million yuan year-on-year
.
China Resources Sanjiu: Net profit increased by 28.
13% year-on-year.
As of the year ended December 31, 2021, China Resources Sanjiu achieved a total operating income of 15.
32 billion yuan, a year-on-year increase of 12.
34%; net profit attributable to shareholders of listed companies was 2.
047 billion yuan, a year-on-year increase.
An increase of 28.
13%; basic earnings per share are 2.
09 yuan, and the proposed cash dividend is 8.
6 yuan (tax included) per 10 shares
.
It is reported that the main reason for the increase in performance is that in 2021, China Resources Sanjiu will continue to carry out innovation, transformation and upgrading, strengthen brand and channel construction, increase innovation investment, improve operation quality and efficiency, stabilize industry position, and achieve double growth in revenue and net profit
.
From the perspective of the company's annual revenue composition, the pharmaceutical business performed relatively well, generating revenue of 14.
626 billion yuan, a year-on-year increase of 11.
77%
.
Among them, CHC health consumer goods business achieved revenue of 9.
276 billion yuan, a year-on-year increase of 17.
72%; prescription drug business achieved revenue of 5.
350 billion yuan, a year-on-year increase of 2.
76%
.
Tigermed: Net profit increased by 64.
4% year-on-year According to Tigermed's 2021 performance report, the annual operating income was about 5.
2135 billion yuan, a year-on-year increase of 63.
3%; the net profit attributable to company owners was 2.
879 billion yuan, a year-on-year increase of 64.
4%; Basic earnings per share of 3.
32 yuan, final dividend of 5 yuan per 10 shares (tax included)
.
Tigermed's main business can be divided into three sections: clinical trial technical services, clinical trial related services and experimental services
.
Among them, the performance of the clinical trial technology service sector is the highlight, and the revenue obtained in 2021 will reach 2.
994 billion yuan, a year-on-year increase of 97.
1%
.
The strong growth in this segment was mainly due to the increase in revenue from clinical trial operations and other services under the clinical trial technical services segment (including medical registration, scientific affairs, medical translation and pharmacovigilance services, etc.
); and related multi-regional clinical trials in the second half of 2021.
income
.
In addition, revenue from clinical trial-related services and laboratory services segment amounted to RMB 2.
22 billion, representing a year-on-year increase of 32.
7%, mainly due to the increase in revenue from laboratory services, on-site management and patient recruitment services, and data management and statistical analysis services
.
Livzon Pharmaceutical: Net profit attributable to the parent was 1.
776 billion yuan, a year-on-year increase of 3.
54% According to Livzon Pharmaceutical's 2021 performance report, during the reporting period, it achieved an operating income of 12.
064 billion yuan, a year-on-year increase of 14.
67%; the net profit attributable to the company's shareholders was 17.
76 100 million yuan, a year-on-year increase of 3.
54%; basic earnings per share were 1.
9 yuan, and a cash dividend of 13.
00 yuan (tax included) was distributed for every 10 shares
.
Regarding the reasons for the growth in performance, the announcement stated that this year, the group's chemical preparations segment saw a significant growth rate in sales, and the sales in key advantageous areas such as digestive tract, gonadotropins, and spirits achieved sustained and rapid year-on-year growth.
The steady increase in profit guarantees the steady growth of the company's overall performance
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.